Noxopharm receives $1.4 million R&D tax incentive rebate Highlights • $1.4 million refund received via Australian Government R&D Tax Incentive scheme • Support for SOF-SKN™ extension study and Sofra™ technology platform Sydney, 12 November 2026: Australian clinical-stage biotechnology...
Noxopharm receives $1.4 million R&D tax incentive rebate
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Noxopharm Ltd. has received a rebate from the Australian Government's R&D Tax Incentive scheme, which will support its ongoing clinical studies and technology platform development. The rebate will specifically aid the SOF-SKN extension study for patients with cutaneous lupus erythematosus and enhance the broader Sofra technology platform.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Noxopharm
- Noxopharm Investor Webinar
- Cleansing Statement
- Application for quotation of securities - NOX
- Proposed issue of securities - NOX
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Noxopharm
- Noxopharm 2026 AGM Chair's Address
- Noxopharm 2026 AGM Corporate Presentation
- Results of Meeting
- Notice of Extraordinary General Meeting/Proxy Form
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm